Marc Goodman UBS
Marc Goodman rises from runner-up to reclaim the No. 3 spot he held in 2008, when he was with Credit Suisse. The analyst moved to UBS in February 2009 and reinitiated coverage on Biovail Corp. one month later with a buy rating, at $10.81, making the case that the Ontario-based maker of Wellbutrin and other antidepressants was well positioned for strong growth. He maintained his position even in June 2010 when Valeant Pharmaceuticals International of Aliso Viejo, California, announced plans to merge with Biovail, telling investors that they should keep “enjoying the ride.” And what a ride it’s been: By late August 2010 the stock had raced to $22.87, an eye-popping 111.6 percent advance. The acquisition is expected to be completed in the fourth quarter.